- Home
- OGN vs NAMS Comparison
OGN vs NAMS Comparison
Compare OGN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGN
- NAMS
- Stock Information
- Founded
- OGN 1923
- NAMS 2019
- Country
- OGN United States
- NAMS Netherlands
- Employees
- OGN N/A
- NAMS N/A
- Industry
- OGN Biotechnology: Pharmaceutical Preparations
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- OGN Health Care
- NAMS Health Care
- Exchange
- OGN Nasdaq
- NAMS Nasdaq
- Market Cap
- OGN 2.7B
- NAMS 2.7B
- IPO Year
- OGN N/A
- NAMS N/A
- Fundamental
- Price
- OGN $10.45
- NAMS $24.49
- Analyst Decision
- OGN Hold
- NAMS Strong Buy
- Analyst Count
- OGN 4
- NAMS 10
- Target Price
- OGN $18.00
- NAMS $41.40
- AVG Volume (30 Days)
- OGN 3.6M
- NAMS 982.1K
- Earning Date
- OGN 10-30-2025
- NAMS 11-05-2025
- Dividend Yield
- OGN 0.76%
- NAMS N/A
- EPS Growth
- OGN N/A
- NAMS N/A
- EPS
- OGN 2.69
- NAMS N/A
- Revenue
- OGN $6,281,000,000.00
- NAMS $64,006,000.00
- Revenue This Year
- OGN N/A
- NAMS N/A
- Revenue Next Year
- OGN $1.36
- NAMS $1.67
- P/E Ratio
- OGN $3.90
- NAMS N/A
- Revenue Growth
- OGN N/A
- NAMS 762.15
- 52 Week Low
- OGN $8.01
- NAMS $14.06
- 52 Week High
- OGN $20.96
- NAMS $27.35
- Technical
- Relative Strength Index (RSI)
- OGN 61.42
- NAMS 48.92
- Support Level
- OGN $10.24
- NAMS $23.05
- Resistance Level
- OGN $10.72
- NAMS $27.35
- Average True Range (ATR)
- OGN 0.40
- NAMS 1.46
- MACD
- OGN 0.07
- NAMS -0.24
- Stochastic Oscillator
- OGN 74.23
- NAMS 33.49
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.